We had previously identified SSX2IP through the immunoscreening of a testis cDNA library with sera from adult AML patients [36] and it was one of the first tumour antigens shown to act as a biomarker for improved OS when its levels were above median at disease diagnosis in adults with AML who lacked detectable cytogenetic rearrangements [42]. This evidence concerns the gene SSX2IP and acute myeloid leukemia.